Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Small Cap Street, LLC
NEW YORK, Feb. 18, 2014 /PRNewswire/ -- New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Life sciences company MetaStat, Inc. (OTCQB: MTST) recently completed a trial of its MetaSite Breast test that confirmed the test's ability to accurately predict whether breast cancer would metastasize. The confirmation paves the way for MetaStat to bring the test to market in 2015. The company predicts that the test could be used to design more customized treatment for 100 percent of the 232,000 newly diagnosed breast cancer patients every year. That represents a $580 million market opportunity for MetaSite Breast test.
The most recent trial followed 481 women who had been diagnosed with breast cancer. Researchers from Albert Einstein College of Medicine and of Yeshiva College and Weill Cornell Medical College used the MetaSite Breast test on each of the 481 women. They found that there was a significant correlation between the tests' predictions and the women whose cancer did metastasize.
MetaSite Breast test is just one of MetaStat's products aimed at identifying cancerous tumors with the potential to metastasize. MenaCalc is a diagnostic test that predicts metastasis based on the amount of Mena protein isoforms that exist in a cancerous tumor sample. That test is scheduled for release between 2015 and 2018 and could be used to predict metastasization in patients with breast, lung, prostate, and colorectal cancer.
MetaStat is one of a handful of biotech companies that are making exciting advances in the world of testing and treating cancer and other deadly diseases. Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) was recently granted Fast Track status by the Food and Drug Administration for its drug levosimendan, which will reduce moridity in patients who have undergone cardiac surgery. A recent test showed that the drug does successfully provide renal benefits for those undergoing mitral valve surgery.
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) is also producing several therapies that are designed to destroy melanoma, lung, and breast cancers while also reducing dangerous side effects. Provectus has completed a Phase One trial of its breast cancer treatment. It's also underway on a Phase One trial of its liver cancer treatment and a Phase Two trial of its treatment for recurrent melanoma.
Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) has two drugs in testing that are designed to treat blood borne cancers. Both drugs have been tested on approximately 300 patients in Phase I and Phase II Trials. The company plans to move the drugs into clinical trials in the next 12 to 18 months.
The vast size of the recurrent and metastatic cancer market combined with the inefficiencies of current tests and treatments makes it an enviable area for biotech companies to target. Led by MetaStat, the industry is on a trajectory to develop immensely profitable products and provide effective, innovative tests and treatments to patients.
These four companies present exciting investment opportunities. Check out our free industry report on MTST, OXBT, PVCT, and ATNM to learn about the products in their pipeline and their massive market potential here. http://bit.ly/AnalystCancerTreatmentReport copy and paste may be required
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared Small Cap Street, LLC and authored by Marc Bonaccci, Chief Analyst. An outsourced research services provider represented by Marc Bonaccci, Chief Analyst, provided Small Cap Street, LLC this article or report. Small Cap Street, LLC is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Marc Bonaccci, Chief Analyst.
NOT FINANCIAL ADVICE
Small Cap Street, LLC makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Small Cap Street, LLC is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Small Cap Street, LLC whatsoever for any direct, indirect or consequential loss arising from the use of this document. Small Cap Street, LLC expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Small Cap Street, LLC does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Companies mentioned have authorized Small Cap Street, LLC to use their ticker symbols in this press release. Companies mentioned have not compensated Small Cap Street, LLC or Marc Bonaccci, Chief Analyst for the creation or dissemination of this report. Small Cap Street, LLC is the party responsible for issuing the press release and for hosting the full analyst report on smallcapir.com. Marc Bonaccci, Chief Analyst, is the author of research report. Information in this release is fact checked and produced on a best efforts basis by Marc Bonaccci, Chief Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
©2012 PR Newswire. All Rights Reserved.